Aurisco(SH:605116)2021-08-30 16:00Financial Performance - Aurisco reported a total revenue of RMB 150 million for the first half of 2021, representing a year-on-year increase of 25%[17]. - The company achieved a net profit of RMB 30 million, which is a 15% increase compared to the same period last year[17]. - The company's operating revenue for the first half of 2021 was ¥401,774,037.47, representing a 4.99% increase compared to ¥382,680,592.84 in the same period last year[22]. - Net profit attributable to shareholders decreased by 19.49% to ¥82,977,089.26 from ¥103,062,918.26 year-on-year[22]. - The net cash flow from operating activities fell by 32.35% to ¥88,783,067.78 compared to ¥131,237,065.89 in the previous year[22]. - Basic earnings per share decreased by 27.59% to ¥0.21 from ¥0.29 in the same period last year[22]. - The company's total operating revenue for the first half of 2021 reached ¥401,774,037.47, an increase of 5.7% compared to ¥382,680,592.84 in the same period of 2020[163]. - Total operating costs increased to ¥309,659,105.28, up 16.9% from ¥264,312,368.86 year-over-year[163]. - Net profit for the first half of 2021 was ¥82,977,089.26, a decrease of 19.5% from ¥103,062,918.26 in the previous year[165]. - The company's total comprehensive income for the first half of 2021 was CNY 64,776,820.02, down 20.6% from CNY 81,629,021.44 in the same period of 2020[173]. Market Expansion and Strategy - Aurisco plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[17]. - The company is exploring potential acquisitions in the biotech sector to diversify its product offerings and enhance its competitive edge[17]. - The company has established partnerships with domestic pharmaceutical firms, significantly enhancing its domestic market expansion efforts[47]. - The company plans to continue focusing on market expansion and new product development to drive future growth[186]. Research and Development - The company is investing RMB 20 million in R&D for new drug formulations, aiming to launch two new products by Q4 2022[17]. - R&D expenses totaled ¥27.96 million, a 30.02% increase from ¥21.51 million, reflecting the company's commitment to product diversification[48]. - Currently, the company has 26 products under development, with multiple new products expected to enter the registration application stage in the next 3-5 years[70]. - The company has established six major engineering technology innovation platforms focused on small molecule drugs, peptide drugs, and innovative drug development[40]. Environmental Responsibility - The company has established a comprehensive environmental risk emergency mechanism and has filed an emergency response plan with local environmental authorities[96]. - The company has implemented an online monitoring system for wastewater and VOC emissions, ensuring compliance with environmental standards[99]. - The company reported a total of 617.3663 tons of solid waste disposed of in the first half of 2021[82]. - The company is maintaining a safety stock of key raw materials to mitigate supply chain risks due to the pandemic[74]. - The company has upgraded its waste gas treatment facilities, reducing the number of exhaust pipes from 15 to 7, enhancing treatment capacity[91]. Financial Management and Shareholder Commitments - The company has committed to a share lock-up period from September 21, 2020, to September 20, 2023, for major shareholders and executives[108]. - The company will implement measures to stabilize stock prices if the closing price falls below the latest audited net asset value per share for 20 consecutive trading days within three years post-listing[125]. - Shareholders must publicly disclose reasons for any breach of lock-up commitments and apologize to other shareholders and the public[115]. - The company will enhance the management of raised funds and ensure their reasonable use to improve profitability and operational efficiency[128]. Operational Efficiency - The company has implemented new strategies to improve operational efficiency, projected to save RMB 5 million annually[17]. - The company completed 26 quality audits in the first half of 2021, significantly up from 11 audits in the entire year of 2020[45]. - The company has established a complete raw material drug sales system across the Americas, Europe, and Asia, collaborating with major pharmaceutical companies[44]. Financial Position - The company's net assets attributable to shareholders increased by 2.67% to ¥1,422,180,104.08 compared to ¥1,385,232,437.06 at the end of the previous year[22]. - Total assets grew by 2.17% to ¥1,566,428,798.87 from ¥1,533,212,830.38 at the end of the last year[22]. - Cash and cash equivalents decreased by 12.67% to ¥492,617,365.14 from ¥564,096,120.31 year-over-year[57]. - Accounts receivable increased by 9.30% to ¥151,501,447.77 from ¥142,628,037.16 year-over-year[57]. - Inventory increased by 12.92% to ¥268,521,526.50 from ¥237,792,190.43 year-over-year[59].